Ribocure supports WORLD KIDNEY DAY on March 14th

Ribocure Pharmaceuticals AB is a clinical stage biotech company developing oligonucleotide-based therapeutics (siRNA). Across the globe, chronic kidney disease (CKD) affects around 700 million people, with 3.1 million deaths attributable to kidney dysfunction, making it the seventh leading cause of mortality worldwide. Low- and middle-income countries bear a disproportionate burden of CKD and kidney failure. Multiple […]

Ribocure supports RARE DISEASE DAY on February 29th

Ribocure Pharmaceuticals AB is a clinical stage biotech company developing oligonucleotide-based therapeutics (siRNA). Our primary focus lies in addressing unmet medical needs in rare diseases by using precision medicine approaches. We are working on several disease areas that include HDV infection, chylomicronemia syndrome (patients with extremely high triglyceride levels and suffering from frequent pancreatitis), as […]

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Mölndal, Sweden, Kunshan, China and Ingelheim, Germany – 3 January 2024 Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The partnership brings together Ribo’s leading experience in the discovery and clinical development of small […]

Portrait of Li-ming Gan in GoCo News

Our CEO has been portrayed in GoCo news. Here he shared his views on how productive collaboration between industry, academia and health sector may contribute to a successful Swedish life science sector. Read the full article here.

Ribo announces the latest research news for three siRNA therapeutic drugs at the European Society of Cardiology Congress 2023

Suzhou Ribo Life Science (Ribo) and Ribocure Pharmaceuticals (Ribocure) presented new data from three projects from its cardiovascular pipeline at the European Society of Cardiology Congress (ESC) in Amsterdam on August 25-28, the world’s largest and most influential conference in cardiology. Building on its proprietary liver-targeting platform RIBO-GalSTAR®, highly specific, potent and durable gene silencing […]

Promising data from our HBV program presented at EASL Congress

Thanks EASL for a great meeting and also the opportunity to simultaneously show data from our HBV program, both with regard to its robust preclinical proof of concept data package as well as the hot off the press interim clinical data from the ongoing Ph1b study. Very excited to see the excellent safety data and […]

Ribocure Pharmaceuticals was officially inaugurated on June 30th 2023

We arranged our inauguration ceremony together with both friends and colleagues from academia and industry, as well as many persons that have contributed to the establishment of Ribocure Pharmaceuticals during the past year. Over 75 persons participated, and guests of honor was the leadership team from the mother company Suzhou Ribo Life Science. And who […]

Privacy Policy (Integritetspolicy)
Your privacy is important to us. Ribocure Pharmaceuticals AB respects your privacy regarding all data we may collect from you on our website, www.ribocure.com.
 
We collect data/information to make contact and establish and maintain a relationship. We collect this information in a fair and legal way with your awareness and consent, as stipulated by GDPR (General Data Protection Regulation). We also let you know why we collect it and how it will be used.
 
The data that is stored are the fields that each submission form contains. We save the data for as long as is necessary with regard to the purposes of the processing. We always base the collection of personal data on consent.
 
You have the right to request information about what personal data we have stored about you. To do this, contact the Data Protection Officer (DPO). You also have the right to request correction or deletion of your personal data at any time.
 
Your continued use of our website will be deemed as acceptance of our privacy and personal information practices. If you have any questions about how we handle user data and personal information, please contact us.
 
Contact information to the Data Protection Officer (DPO):
 
Data Protection Officer
Ribocure Pharmaceuticals AB
Vetenskapens gränd 11
431 53 Mölndal
Sweden
 
E-mail: dpo@ribocure.com